Biologics in combination with chemotherapy for gastric cancer: is this the answer?

Area of Science:

• Oncology
• Gastroenterology
• Pharmacology

Background:

• Gastric cancer (GC) is a major global health concern and the third leading cause of cancer mortality.
• Current treatment options for both curable and metastatic GC have seen minimal advancement, with only trastuzumab and ramucirumab approved in recent decades.
• Limited effective therapies exist for patients progressing beyond second-line treatment.

Discussion:

• The Cancer Genome Atlas identified four GC genotypes, but these findings have yet to significantly alter clinical strategies.
• The established front-line chemotherapy regimen of platinum compounds and fluoropyrimidines serves as a suitable platform for incorporating novel biologic agents.
• While the development of new cytotoxic agents has slowed, chemotherapy remains a vital component of GC treatment.

Key Insights:

• Biologic agents that modulate the host immune system are a promising avenue for GC therapy.
• Targeting specific signaling pathways frequently exploited by GC cells, such as EGFR, mTOR, angiogenesis, and MET, is a key focus.
• Combination therapy, integrating biologics with existing chemotherapy, holds potential for enhanced efficacy.

Outlook:

• Further research into GC genotypes is necessary to refine personalized treatment approaches.
• Continued investigation into targeted therapies and immunomodulatory agents is crucial for advancing GC care.
• The integration of novel biologic agents into standard chemotherapy regimens is expected to improve outcomes for gastric cancer patients.